Compare ASTRAZENECA PHARMA with FDC - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs FDC - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA FDC ASTRAZENECA PHARMA/
FDC
 
P/E (TTM) x 116.0 19.9 583.3% View Chart
P/BV x 35.5 3.8 923.5% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   FDC
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
FDC
Mar-18
ASTRAZENECA PHARMA/
FDC
5-Yr Chart
Click to enlarge
High Rs1,278319 400.6%   
Low Rs883164 538.2%   
Sales per share (Unadj.) Rs228.461.6 370.5%  
Earnings per share (Unadj.) Rs10.49.9 104.2%  
Cash flow per share (Unadj.) Rs16.312.0 135.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.873.2 135.0%  
Shares outstanding (eoy) m25.00174.40 14.3%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.73.9 120.7%   
Avg P/E ratio x104.224.3 429.4%  
P/CF ratio (eoy) x66.420.2 329.1%  
Price / Book Value ratio x10.93.3 331.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,00842,118 64.1%   
No. of employees `0001.45.5 24.5%   
Total wages/salary Rs m1,5352,167 70.9%   
Avg. sales/employee Rs Th4,210.91,943.7 216.6%   
Avg. wages/employee Rs Th1,132.2391.7 289.0%   
Avg. net profit/employee Rs Th191.1313.7 60.9%   
INCOME DATA
Net Sales Rs m5,71010,751 53.1%  
Other income Rs m123510 24.0%   
Total revenues Rs m5,83311,260 51.8%   
Gross profit Rs m4632,267 20.4%  
Depreciation Rs m147351 41.9%   
Interest Rs m014 0.0%   
Profit before tax Rs m4382,411 18.2%   
Minority Interest Rs m0-5 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179671 26.7%   
Profit after tax Rs m2591,735 14.9%  
Gross profit margin %8.121.1 38.4%  
Effective tax rate %40.827.8 146.7%   
Net profit margin %4.516.1 28.1%  
BALANCE SHEET DATA
Current assets Rs m3,2097,213 44.5%   
Current liabilities Rs m2,0702,104 98.4%   
Net working cap to sales %20.047.5 42.0%  
Current ratio x1.63.4 45.2%  
Inventory Days Days7254 132.7%  
Debtors Days Days3528 126.0%  
Net fixed assets Rs m7906,865 11.5%   
Share capital Rs m50175 28.5%   
"Free" reserves Rs m2,41912,586 19.2%   
Net worth Rs m2,46912,761 19.4%   
Long term debt Rs m06 0.0%   
Total assets Rs m4,60515,041 30.6%  
Interest coverage xNM173.2-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.7 173.5%   
Return on assets %5.611.6 48.4%  
Return on equity %10.513.6 77.2%  
Return on capital %17.719.0 93.6%  
Exports to sales %012.3 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA1,327 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3001,889 15.9%   
Fx outflow Rs m2,0150-   
Net fx Rs m-1,7151,889 -90.8%   
CASH FLOW
From Operations Rs m881,498 5.9%  
From Investments Rs m-94201 -46.5%  
From Financial Activity Rs mNA-1,694 0.0%  
Net Cashflow Rs m-610 -55.3%  

Share Holding

Indian Promoters % 0.0 68.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.7 6.4%  
FIIs % 15.7 7.5 209.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 19.0 47.9%  
Shareholders   12,856 23,730 54.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   NEULAND LABS  DR. REDDYS LAB  GSK PHARMA  ALEMBIC  PROCTER & GAMBLE HEALTH  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher, Coal India and UPL Among Top Gainers(Closing)

Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

FDC LTD. Announces Quarterly Results (3QFY20); Net Profit Up 67.7% (Quarterly Result Update)

Feb 10, 2020 | Updated on Feb 10, 2020

For the quarter ended December 2019, FDC LTD. has posted a net profit of Rs 733 m (up 67.7% YoY). Sales on the other hand came in at Rs 3 bn (up 26.0% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. Announces Quarterly Results (2QFY20); Net Profit Up 45.4% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, FDC LTD. has posted a net profit of Rs 627 m (up 45.4% YoY). Sales on the other hand came in at Rs 3 bn (up 28.8% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Penny Stock Master Series: The Quest for 10X Profits in 10 Years(Profit Hunter)

Feb 12, 2021

This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 25, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS